B cells are associated with survival and immunotherapy response in sarcoma

Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50 histological subtypes 1 , 2 . The clinical presentation of patients with different subtypes is often atypical, and responses to therapies such as immune checkpoint blockade vary widely 3 , 4 . To explain this clinical variability, here we study gene expression profiles in 608 tumours across subtypes of soft-tissue sarcoma. We establish an immune-based classification on the basis of the composition of the tumour microenvironment and identify five distinct phenotypes: immune-low (A and B), immune-high (D and E), and highly vascularized (C) groups. In situ analysis of an independent validation cohort shows that class E was characterized by the presence of tertiary lymphoid structures that contain T cells and follicular dendritic cells and are particularly rich in B cells. B cells are the strongest prognostic factor even in the context of high or low CD8 + T cells and cytotoxic contents. The class-E group demonstrated improved survival and a high response rate to PD1 blockade with pembrolizumab in a phase 2 clinical trial. Together, this work confirms the immune subtypes in patients with soft-tissue sarcoma, and unravels the potential of B-cell-rich tertiary lymphoid structures to guide clinical decision-making and treatments, which could have broader applications in other diseases. Immune profiling of the tumour microenvironment of soft-tissue sarcoma identifies a group of patients with high levels of B-cell infiltration and tertiary lymphoid structures that have improved survival and a high response rate to immune checkpoint blockade therapy.

[1]  P. Meltzer,et al.  Mechanisms of sarcoma development , 2003, Nature Reviews Cancer.

[2]  G. Freeman,et al.  Programmed Death-1 (PD-1) is a Marker of Germinal Center-associated T Cells and Angioimmunoblastic T-Cell Lymphoma , 2006, The American journal of surgical pathology.

[3]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[4]  Trevor Hastie,et al.  Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling , 2009, Oncogene.

[5]  Derek Y. Chiang,et al.  Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy , 2010, Nature Genetics.

[6]  Rafael A Irizarry,et al.  Frozen robust multiarray analysis (fRMA). , 2010, Biostatistics.

[7]  J. Blay,et al.  Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity , 2010, Nature Medicine.

[8]  T. Yeatman,et al.  Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. , 2011, The American journal of pathology.

[9]  F. Chibon,et al.  New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics , 2011, The Journal of pathology.

[10]  R. Sciot,et al.  Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors , 2011, Clinical Cancer Research.

[11]  Li-Xuan Qin,et al.  Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. , 2011, Cancer research.

[12]  T. Dønnem,et al.  Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas , 2012, BMC Clinical Pathology.

[13]  P. Watson,et al.  CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer , 2012, Clinical Cancer Research.

[14]  T. Dønnem,et al.  High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator , 2012, Oncoimmunology.

[15]  Benjamin Haibe-Kains,et al.  CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. , 2013, The Journal of clinical investigation.

[16]  Olivier Delattre,et al.  Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Jang,et al.  Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas , 2013, PloS one.

[18]  C. Sautès-Fridman,et al.  Tertiary lymphoid structures in cancer and beyond. , 2014, Trends in immunology.

[19]  N. Rioux-Leclercq,et al.  Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting , 2015, Clinical Cancer Research.

[20]  G. Freeman,et al.  Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer , 2015, Clinical Cancer Research.

[21]  Narasimhan P. Agaram,et al.  Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. , 2015, Human pathology.

[22]  R. Boidot,et al.  Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients , 2016, Oncoimmunology.

[23]  B. Nelson,et al.  Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer , 2016, Clinical Cancer Research.

[24]  S. Paydaş,et al.  Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas , 2016, Medical Oncology.

[25]  L. Bixby,et al.  A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases , 2016, Clinical Cancer Research.

[26]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[27]  J. Blay,et al.  PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas , 2017, Oncoimmunology.

[28]  Y. Fujisawa,et al.  Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma , 2017, Oncoimmunology.

[29]  J. Crowley,et al.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[30]  Robin L. Jones,et al.  T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas , 2017, Cancer.

[31]  A. Reyniès,et al.  Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies , 2018, Cancer Immunology, Immunotherapy.

[32]  Steven J. M. Jones,et al.  Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas , 2017, Cell.

[33]  B. Nelson,et al.  Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer , 2018, Clinical Cancer Research.

[34]  Holger Moch,et al.  Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. , 2018, Cancer research.

[35]  C. Antonescu,et al.  Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. , 2018, The Lancet. Oncology.

[36]  R. Stupp,et al.  Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer , 2017, Oncoimmunology.

[37]  C. Sautès-Fridman,et al.  Tertiary lymphoid structures in the era of cancer immunotherapy , 2019, Nature Reviews Cancer.

[38]  H. Tawbi,et al.  Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. , 2019, Journal of Clinical Oncology.

[39]  Impact of Aurora kinase A and B expression on response to neoadjuvant chemotherapy and patient outcome in muscle-invasive bladder cancer (MIBC). , 2019, Journal of Clinical Oncology.

[40]  Jeffrey E. Lee,et al.  B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.